Delaware 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) of incorporation or organization) For the quarterly period ended September 30, 2023 (Exact name of Company as specified in its charter) Table of Contents Commission File Number: 001-36081 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q NANOVIRICIDES, INC. QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 1 Controls Drive Shelton, Connecticut 06484 (Address ...

Financial Performance - For the year ended June 30, 2023, the company reported a net loss of approximately $8,589,000, compared to a net loss of approximately $8,107,000 for the year ended June 30, 2022, reflecting an increase of $482,000 attributed to higher license milestone expenses [507]. - The company has an accumulated deficit of approximately $131,081,000 as of June 30, 2023, with no revenues generated and no revenues anticipated in the foreseeable future [515]. - The company has not generated any revenues since its inception in May 2005 and does not expect to generate revenues in the near future [500]. - Interest income increased to approximately $356,000 for the year ended June 30, 2023, compared to approximately $12,000 for the year ended June 30, 2022, due to higher interest rates [504]. - The company has approximately $2,034,000 in liabilities as of June 30, 2023, compared to approximately $413,000 as of June 30, 2022 [514]. Cash and Funding - As of June 30, 2023, the company had approximately $8,150,000 in cash and cash equivalents, down from approximately $14,066,000 as of June 30, 2022 [514]. - The Company has approximately $8,150,000 in cash and cash equivalents, expected to fund operations through October 2024 [516]. - The Company has filed a registration statement allowing for the sale of up to $150 million in various securities, with the entire amount still available for sale [518]. - The Company anticipates needing additional funding for later stages of human clinical trials unless a partnership with a larger pharmaceutical company is formed [521]. - The Company intends to seek non-dilutive financing, grants, and pharmaceutical partnerships as its drug candidates progress [532]. Research and Development - Research and development expenses increased to approximately $6,392,000 for the year ended June 30, 2023, up from approximately $5,785,000 for the year ended June 30, 2022, primarily due to increased license fees [503]. - The Company plans to file an IND for its Shingles Skin Cream after advancing its pan-coronavirus and RSV program drugs into clinical trials [511]. - The Company plans to file an IND for the Shingles Skin Cream after advancing its pan-coronavirus and RSV programs into clinical trials [517]. - The estimated costs for Phase I clinical trials are approximately $1.5 million, $5 million for Phase II, and $10 million for Phase III, assuming successful prior phases [522]. - The planned recruitment for Phase 1a/1b clinical trials includes 36 healthy volunteers and 36 COVID patients [524]. - The Company has limited experience in pharmaceutical drug development, leading to potential inaccuracies in budget estimates [526]. - The Company is classified as a clinical drug development stage company and will continue until regulatory approvals are obtained [533]. Strategic Partnerships - The company has signed several cooperative research and development agreements with TheraCour and expects to enter into additional agreements with other entities [509]. - The company plans to actively pursue co-development and licensing agreements with other pharmaceutical companies to enhance revenue opportunities [497]. - The Company believes its market capitalization will improve as its coronavirus program matures through human clinical trials [523].

[PART I FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20FINANCIAL%20INFORMATION) [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed financial statements for the period ended March 31, 2023, including balance sheets, statements of operations, and cash flows, reporting a net loss of $1.7 million for the quarter and $5.0 million for the nine months [Condensed Balance Sheets](index=3&type=section&id=Condensed%20Balance%20Sheets) | Balance Sheet Highlights | March 31, 2023 (Unaudited) | June 30, 2022 | | :--- | :--- | :--- | | Cash and cash equivalents | $9,650,958 | $14,066,359 | | Total current assets | $9,931,075 | $14,416,380 | | Total assets | $18,576,799 | $23,494,862 | | Total current liabilities | $348,744 | $412,837 | | Total stockholders' equity | $18,228,055 | $23,082,025 | - Cash and cash equivalents decreased by approximately **$4.4 million**, reflecting cash used in operations[9](index=9&type=chunk) [Condensed Statements of Operations](index=4&type=section&id=Condensed%20Statements%20of%20Operations) | Operating Results (Unaudited) | Three Months Ended Mar 31, 2023 | Three Months Ended Mar 31, 2022 | Nine Months Ended Mar 31, 2023 | Nine Months Ended Mar 31, 2022 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $1,196,094 | $1,255,074 | $3,479,463 | $4,613,302 | | General and administrative | $614,647 | $532,801 | $1,787,632 | $1,707,514 | | **Loss from operations** | **($1,810,741)** | **($1,787,875)** | **($5,267,095)** | **($6,320,816)** | | **Net loss** | **($1,702,804)** | **($1,792,664)** | **($5,018,580)** | **($6,326,866)** | | Net loss per share | ($0.15) | ($0.16) | ($0.43) | ($0.55) | - Net loss for the nine months ended March 31, 2023, decreased due to lower research and development expenses[11](index=11&type=chunk) [Condensed Statements of Cash Flows](index=7&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) | Cash Flow Summary (Unaudited) | Nine Months Ended March 31, 2023 | Nine Months Ended March 31, 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | ($4,171,467) | ($4,493,550) | | Net cash used in investing activities | ($149,146) | ($248,986) | | Net cash used in financing activities | ($94,788) | ($202,007) | | **Net change in cash** | **($4,415,401)** | **($4,944,543)** | | Cash at end of period | $9,650,958 | $15,572,134 | [Notes to the Condensed Financial Statements](index=8&type=section&id=Notes%20to%20the%20Condensed%20Financial%20Statements) These notes provide crucial context to the financial statements, detailing the company's clinical-stage status, lead drug candidate NV-CoV-2 entering Phase 1 trials, liquidity position, and significant related-party transactions - The company is a clinical-stage biopharmaceutical firm with its lead candidate, **NV-CoV-2 for COVID-19**, entering Phase 1a/1b human clinical trials in India[20](index=20&type=chunk)[21](index=21&type=chunk) - As of March 31, 2023, the company had an accumulated deficit of approximately **$127.5 million** and no revenue, but management believes **$9.7 million** in cash is sufficient for at least 12 months of operations[27](index=27&type=chunk)[30](index=30&type=chunk) - The company holds exclusive worldwide licenses from **TheraCour Pharma, Inc.**, a related party, for its core technology, with a **15% royalty** on net sales upon commercialization[24](index=24&type=chunk) - The company licensed its COVID-19 drug candidates to **Karveer Meditech** for clinical development and commercialization in India, with NanoViricides reimbursing trial costs plus a **30% fee** and receiving a **70% royalty** on net sales[40](index=40&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=17&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's business, drug pipeline, and financial performance, focusing on advancing **NV-CoV-2** into human clinical trials and expanding **NV-387**'s use against other viruses, with a net loss of **$5.0 million** for the nine months [Drug Pipeline and Strategy](index=17&type=section&id=Drug%20Pipeline%20and%20Strategy) - The lead clinical-stage drug, **NV-CoV-2** for COVID-19, is poised to enter Phase 1a/1b trials in India[66](index=66&type=chunk)[75](index=75&type=chunk) - The company is exploring additional applications for **NV-387**, the active ingredient in NV-CoV-2, against other viruses like RSV and mpox[68](index=68&type=chunk)[85](index=85&type=chunk)[92](index=92&type=chunk) - The company's platform technology develops drugs resistant to viral mutation by mimicking human cellular receptors[108](index=108&type=chunk)[109](index=109&type=chunk) - NanoViricides possesses its own **cGM-compliant manufacturing facility**, providing a competitive advantage for rapid and cost-effective production of clinical trial materials[103](index=103&type=chunk)[104](index=104&type=chunk) [Recent Developments and Financial Status](index=30&type=section&id=Recent%20Developments%20and%20Financial%20Status) - During the quarter, the company completed **cGM-compliant manufacturing** of **NV-387** and **NV-CoV-2 Oral Syrup and Gummies** for clinical trials in India[124](index=124&type=chunk) - Subsequent to the quarter, drug products were shipped to partner **Karveer** in India on April 12, 2023, with clinical trials expected to commence shortly[125](index=125&type=chunk) - As of March 31, 2023, the company held **$9.7 million** in cash and cash equivalents, deemed sufficient to fund operations for over twelve months and initial human clinical trials for **NV-CoV-2**[128](index=128&type=chunk)[129](index=129&type=chunk) [Results of Operations Analysis](index=41&type=section&id=Results%20of%20Operations%20Analysis) | Expense Category | Nine Months Ended Mar 31, 2023 | Nine Months Ended Mar 31, 2022 | Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Research & Development | $3,479,463 | $4,613,302 | ($1,133,839) | Decrease in external lab expenses and a prior-year milestone payment | | General & Administrative | $1,787,632 | $1,707,514 | $80,118 | Increase in professional fees | - The net loss for the nine months ended March 31, 2023, was **$5.02 million** (or **$0.43 per share**), a decrease from **$6.33 million** (or **$0.55 per share**) in the prior year period[182](index=182&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=44&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's market risk exposure is primarily limited to non-material interest rate fluctuations on cash equivalents, with no foreign currency or derivative instrument exposure - The company's market risk exposure is primarily limited to **non-material interest rate risk** on its cash equivalents[188](index=188&type=chunk) [Controls and Procedures](index=44&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were ineffective as of March 31, 2023, due to a material weakness in internal control over financial reporting, with a remediation plan in place - Disclosure controls and procedures were deemed **ineffective** as of March 31, 2023, due to a **material weakness** in internal control over financial reporting[190](index=190&type=chunk) - The material weakness arises from insufficient timely review of the period-end closing process and inadequate personnel and resources[190](index=190&type=chunk) - A remediation plan, including a **financial reporting controls committee**, is in place to enhance oversight and ensure financial reporting reliability[192](index=192&type=chunk) [PART II OTHER INFORMATION](index=46&type=section&id=PART%20II%20OTHER%20INFORMATION) [Legal Proceedings](index=46&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no pending or threatened legal proceedings expected to materially adversely affect its business, financial condition, or results of operations - As of the filing date, there are **no legal proceedings** against the company, nor is the company aware of any threatened actions[197](index=197&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=46&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section details the issuance of unregistered equity securities, including Series A preferred stock, common stock, and warrants, as compensation to various parties under Section 4(a)(2) exemptions - Issued **Series A preferred stock** and **common stock** for employee, director, and consulting services[198](index=198&type=chunk)[199](index=199&type=chunk)[201](index=201&type=chunk)[202](index=202&type=chunk) - Granted fully vested warrants to the **Scientific Advisory Board** to purchase common stock shares[200](index=200&type=chunk) - All securities were issued without registration under the Securities Act, relying on **Section 4(a)(2) exemptions**, and are considered restricted[203](index=203&type=chunk) [Defaults Upon Senior Securities](index=46&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) No defaults upon senior securities were reported during the period - The company reported **no defaults** upon senior securities[204](index=204&type=chunk) [Mine Safety Disclosures](index=48&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's operations - This disclosure item is **not applicable**[205](index=205&type=chunk) [Other Information](index=48&type=section&id=Item%205.%20Other%20Information) No other material information was reported - The company reported **no other information**[206](index=206&type=chunk) [Exhibits](index=49&type=section&id=Item%206.%20Exhibits%20and%20Reports%20on%20Form%208-K) This section lists the exhibits filed with the Form 10-Q, including CEO and CFO certifications and Inline XBRL documents - Exhibits filed include **Rule 13(a)-14(a)/15(d)-14(a)** and **Section 1350 certifications** for the CEO and CFO, along with Inline XBRL files[208](index=208&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2022 Commission File Number: 001-36081 (Exact name of Company as specified in its charter) of incorporation or organization) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) 1 Controls Drive Shelton, Connecticut 06484 (Address of principal executive ...

PART I FINANCIAL INFORMATION [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) The company reported a net loss of $1.6 million for Q3 2022, with total assets decreasing to $22.1 million and cash at $12.9 million [Balance Sheets](index=3&type=section&id=Balance%20Sheets) Total assets decreased to $22.1 million by September 30, 2022, primarily due to reduced cash, while equity declined to $21.6 million Balance Sheet Summary (in thousands) | Balance Sheet Items | Sep 30, 2022 (Unaudited) | June 30, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $12,918 | $14,066 | | Total current assets | $13,150 | $14,416 | | Property and equipment, net | $8,557 | $8,694 | | Total assets | $22,082 | $23,495 | | **Liabilities & Equity** | | | | Total current liabilities | $518 | $413 | | Total stockholders' equity | $21,564 | $23,082 | | Total liabilities and stockholders' equity | $22,082 | $23,495 | [Statements of Operations](index=4&type=section&id=Statements%20of%20Operations) Net loss for Q3 2022 improved to $1.57 million ($0.14 per share) from $2.61 million in Q3 2021, driven by lower R&D expenses Statement of Operations Summary (in thousands) | Metric | Q3 2022 (3 months ended Sep 30) | Q3 2021 (3 months ended Sep 30) | | :--- | :--- | :--- | | Research and development | $1,112.7 | $2,096.9 | | General and administrative | $509.7 | $515.4 | | Total operating expenses | $1,622.4 | $2,612.4 | | Loss from operations | $(1,622.4) | $(2,612.4) | | Net loss | $(1,570.6) | $(2,613.1) | | Net loss per share | $(0.14) | $(0.23) | [Statements of Cash Flows](index=7&type=section&id=Statements%20of%20Cash%20Flows) Net cash used in operating activities increased to $1.03 million, resulting in a $1.15 million net decrease in cash, ending at $12.9 million Cash Flow Summary (in thousands) | Cash Flow Activity | Q3 2022 (3 months ended Sep 30) | Q3 2021 (3 months ended Sep 30) | | :--- | :--- | :--- | | Net cash used in operating activities | $(1,032.9) | $(724.2) | | Net cash used in investing activities | $(44.5) | $(24.3) | | Net cash used in financing activities | $(71.0) | $(71.3) | | Net change in cash | $(1,148.3) | $(819.9) | | Cash at end of period | $12,918.0 | $19,696.8 | [Notes to the Financial Statements](index=8&type=section&id=Notes%20to%20the%20Financial%20Statements) The notes detail the company's antiviral R&D, accumulated deficit of $124 million, going concern status, and related-party transactions - The company's lead drug program is NV-CoV-2 for COVID-19, for which IND-enabling studies are complete. The company is preparing for Phase I/II human clinical trials[21](index=21&type=chunk) - New limited drug development programs have been initiated for Monkeypox virus (MPXV) and Enterovirus D68 (EV68) in response to recent outbreaks[22](index=22&type=chunk)[23](index=23&type=chunk) - As of September 30, 2022, the company had an accumulated deficit of approximately **$124 million** and has not generated any revenue. Management believes existing cash of **$12.9 million** is sufficient to fund operations for at least the next 12 months[29](index=29&type=chunk)[35](index=35&type=chunk) - The company has an At The Market (ATM) sales agreement for up to **$50 million**, under which it previously sold **$6.1 million** worth of common stock in March 2021[31](index=31&type=chunk)[32](index=32&type=chunk) - The company has exclusive license agreements with TheraCour Pharma, Inc., an entity controlled by the company's CEO, for its core technology. In Q3 2021, a milestone payment of **100,000 Series A preferred shares** (valued at **$935,088**) was made to TheraCour under the COVID-19 license agreement[26](index=26&type=chunk)[27](index=27&type=chunk)[41](index=41&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=18&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the development-stage biopharma's lead COVID-19 drug candidates, manufacturing capabilities, reduced net loss, and future capital needs [Organization and Nature of Business](index=20&type=section&id=Organization%20and%20Nature%20of%20Business) NanoViricides is a development-stage antiviral drug company with lead COVID-19 candidates, in-house cGMP manufacturing, and broad-spectrum technology - The company's most advanced drug candidates, NV-CoV-2 and NV-CoV-2-R, are for COVID-19. The company is working towards filing an IND for NV-CoV-2 to begin human clinical trials[65](index=65&type=chunk) - NanoViricides possesses its own cGMP-compliant manufacturing facility, enabling it to produce clinical supplies of its drug candidates, which simplifies and expedites manufacturing operations[76](index=76&type=chunk) - The company has developed multiple formulations for NV-CoV-2, including oral gummies, oral syrup, and a solution for injection, infusion, or inhalation, to treat different patient populations and disease severities[82](index=82&type=chunk)[94](index=94&type=chunk) - The company's technology platform is based on biomimetic engineering, creating drugs that viruses are unlikely to escape through mutation. This is a key differentiator from vaccines and antibody therapies that have lost effectiveness against new variants[77](index=77&type=chunk)[80](index=80&type=chunk) [Financial Status and Drug Programs](index=31&type=section&id=Financial%20Status%20and%20Drug%20Programs) The company holds $12.9 million in cash, sufficient for initial trials, with a pipeline focused on COVID-19, HerpeCide™, Monkeypox, and Enterovirus - As of September 30, 2022, the company had approximately **$12.9 million** in cash and cash equivalents, which is considered sufficient for more than twelve months of operations at the current expenditure rate[117](index=117&type=chunk)[118](index=118&type=chunk) - The company's drug pipeline priority is: 1) COVID-19 (NV-CoV-2), 2) HerpeCide™ program (NV-HHV-1 for shingles, followed by HSV-1/HSV-2), and 3) newly initiated programs for Monkeypox and Enterovirus[120](index=120&type=chunk)[121](index=121&type=chunk)[122](index=122&type=chunk) - The market for anti-viral drugs was estimated at **$40 billion** in 2018 and projected to be **$65.5 billion** in 2023, excluding the COVID-19 market, indicating a large potential market for the company's pipeline[124](index=124&type=chunk) - The company has demonstrated cGMP manufacturing capabilities for complex nanomedicine drugs at its own facility, a significant milestone that saves time and money compared to using external contract manufacturers[133](index=133&type=chunk)[134](index=134&type=chunk)[135](index=135&type=chunk) [Results of Operations](index=53&type=section&id=Results%20of%20Operations) Net loss decreased to $1.6 million due to a $0.98 million reduction in R&D expenses, primarily from a prior-year non-cash milestone payment Comparison of Operating Results (in thousands) | Expense Category | Q3 2022 (3 months ended Sep 30) | Q3 2021 (3 months ended Sep 30) | Change | | :--- | :--- | :--- | :--- | | Research and Development | $1,112.7 | $2,096.9 | $(984.2) | | General and Administration | $509.7 | $515.4 | $(5.7) | | Net Loss | $(1,570.6) | $(2,613.1) | $1,042.5 | - The decrease in R&D expenses was mainly due to a one-time milestone payment in Q3 2021, where **100,000 shares of Series A preferred stock** (fair value ~**$935,000**) were issued to TheraCour for the COVID-19 license[230](index=230&type=chunk) [Liquidity and Capital Reserves](index=54&type=section&id=Liquidity%20and%20Capital%20Reserves) With $12.9 million in cash, the company has sufficient liquidity for 12 months but requires additional capital for long-term R&D and trials, with an ATM agreement in place - The company has an accumulated deficit of **$124.1 million** as of September 30, 2022, and expects losses to continue[236](index=236&type=chunk) - An At The Market (ATM) Sales Agreement for up to **$50 million** is in place, providing a mechanism to raise capital. To date, approximately **$6.4 million** has been raised under this agreement[236](index=236&type=chunk) - Management believes existing resources are sufficient for the next twelve months, but long-term plans, including later-stage clinical trials, will require additional capital[237](index=237&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=40&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces minimal market risk, primarily non-material interest rate risk on cash equivalents, with no foreign currency exposure - The company's primary market risk is interest rate risk associated with short-term cash equivalents, which is deemed non-material[242](index=242&type=chunk) - The company has no foreign operations and is not exposed to foreign currency fluctuations[242](index=242&type=chunk) [Controls and Procedures](index=41&type=section&id=Item%204.%20Controls%20and%20Procedures) Disclosure controls and procedures were ineffective due to a material weakness in financial reporting, with a remediation plan including a new controls committee - Management concluded that disclosure controls and procedures were not effective as of September 30, 2022[244](index=244&type=chunk) - The ineffectiveness is due to an unremediated material weakness in internal control over financial reporting, stemming from inadequate resources and review of the period-end closing process[244](index=244&type=chunk) - A remediation plan has been initiated, which includes a new financial reporting controls committee to provide oversight and ensure reliability and accuracy[246](index=246&type=chunk) PART II OTHER INFORMATION [Legal Proceedings](index=42&type=section&id=Item%201.%20Legal%20Proceedings) There are no pending or threatened legal proceedings against the company as of the filing date - There are no pending or threatened legal proceedings against the Company as of the filing date[250](index=250&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=42&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company issued unregistered equity securities, including preferred and common stock, and warrants, for compensation and services during the quarter - Issued **10,204 shares of Series A preferred stock** to CEO Dr. Anil Diwan as part of a one-year employment agreement extension[251](index=251&type=chunk) - Issued a total of **17,864 shares of common stock** for consulting and director services, and warrants to purchase **286 shares of common stock** to the Scientific Advisory Board[253](index=253&type=chunk)[254](index=254&type=chunk)[255](index=255&type=chunk) - All securities were issued without registration under the Securities Act, in reliance on exemptions provided by Section 4(a)(2) and Rule 506(b) of Regulation D[256](index=256&type=chunk) [Exhibits](index=43&type=section&id=Item%206.%20Exhibits%20and%20Reports%20on%20Form%208-K) This section lists exhibits filed with the Form 10-Q, including CEO/CFO certifications and Inline XBRL data files - Exhibits filed include CEO and CFO certifications (31.1, 31.2, 32.1, 32.2) and Inline XBRL documents (101 series)[262](index=262&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2022 Commission File Number 001-36081 NANOVIRICIDES, INC. (Name of Business Issuer in Its Charter) (State or other jurisdiction of incorporation or NEVADA 76-0674577 (I.R.S. Employer Identification No.) organization) 1 CONTROLS DRIVE, SHELTON, CONNECTICUT, 06484 (Address of principal execu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2022 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) of incorporation or organization) 1 Controls Drive Shelton, Connecticut 06484 (Address of princ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) of incorporation or organization) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) 1 Controls Drive Shelton, Connecticut 06484 (Address of principal executive offices and zip code) (203) 937 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2021 Indicate by check mark whether the Company (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Company was required to file such reports), and (2) has been subject to such f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2021 NANOVIRICIDES, INC. (Name of Business Issuer in Its Charter) (State or other jurisdiction of incorporation or organization) NEVADA 76-0674577 (I.R.S. Employer Identification No.) 1 CONTROLS DRIVE, SHELTON, CONNECTICUT, 06484 (Address of principal executive offices) 203-937-6137 (Issuer's telephone numb ...